HBV Env Targeting TCR(Corregene Biotechnology)

HBV特异性TCR蛋白药物（可瑞生物）

Report date: 2022/08/26 16:13:13

Base Information

Drug NameHBV Env Targeting TCR(Corregene Biotechnology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionRecombinant envelope protein inhibitors
TargetsRecombinant envelope protein
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCorregene Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCorregene Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A